PE20010745A1 - Diazepanes como inhibidores de la interaccion del antigeno lfa-1 y la molecula de adhesion intracelular (icam) - Google Patents
Diazepanes como inhibidores de la interaccion del antigeno lfa-1 y la molecula de adhesion intracelular (icam)Info
- Publication number
- PE20010745A1 PE20010745A1 PE2000001087A PE0010872000A PE20010745A1 PE 20010745 A1 PE20010745 A1 PE 20010745A1 PE 2000001087 A PE2000001087 A PE 2000001087A PE 0010872000 A PE0010872000 A PE 0010872000A PE 20010745 A1 PE20010745 A1 PE 20010745A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- icam
- naphthylmethyl
- arylalkyl
- alkylene
- Prior art date
Links
- 102100022339 Integrin alpha-L Human genes 0.000 title abstract 2
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 title abstract 2
- 102000036639 antigens Human genes 0.000 title abstract 2
- 108091007433 antigens Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 230000003993 interaction Effects 0.000 title abstract 2
- 230000003834 intracellular effect Effects 0.000 title abstract 2
- -1 AMINO, PHENYL Chemical class 0.000 abstract 4
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical class [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical group 0.000 abstract 2
- 208000028867 ischemia Diseases 0.000 abstract 2
- 208000005189 Embolism Diseases 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 abstract 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- 229940124599 anti-inflammatory drug Drugs 0.000 abstract 1
- 235000010290 biphenyl Nutrition 0.000 abstract 1
- 239000004305 biphenyl Substances 0.000 abstract 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 abstract 1
- 239000002955 immunomodulating agent Substances 0.000 abstract 1
- 229940121354 immunomodulator Drugs 0.000 abstract 1
- 230000002584 immunomodulator Effects 0.000 abstract 1
- 239000003018 immunosuppressive agent Substances 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 210000000936 intestine Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 abstract 1
- 229940080818 propionamide Drugs 0.000 abstract 1
- 230000010410 reperfusion Effects 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
- 239000002699 waste material Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
Abstract
SE REFIERE A DIAZEPAN DE FORMULA I, DONDE n ES 1-3; R1 ES H, ALQUILO C1-C4, ARILO, ARILALQUILO C1-C4; Y ES ALQUILENO C1-C4, CO-CH2-ALQUILENO C1-C4, CO-CH2-ALQUENILENO C2-C5, CONH; R2 ES UN RESIDUO AROMATICO, HETEROAROMATICO OPCIONALMENTE SUSTITUIDO CON CF3, HALOGENO, OH, ALCOXILO C1-C4, AMINO, FENILO, BENCILO, ALQUILO C1-C4; R3 ES UN O-AMINOACIDO; R4 ES BIFENILO, BENCILO, HIDROXIBENCILO, O-NAFTILMETILO, ß-NAFTILMETILO, 5,6,7,8-TETRAHIDRO-ß-NAFTILMETILO, INDOLILMETILO OPCIONALMENTE SUSTITUIDO SOBRE EL ANILLO POR CF3, HALOGENO, OH, ALCOXILO C1-C4, AMINO, ENTRE OTROS; X ES CN, NR5R6, OR8; R5 ES H, ALQUILO C1-C6, ARIL, ARILALQUILO C1-C4; R6 ES H, ALQUILO C1-C6; R7 ES H, ALQUILO C1-C4, ARILO, ARILALQUILO C1-C4. UN COMPUESTO PREFERIDO ES (R)-2-[(3S,5R)-5-METIL-2-OXO-3-FENIL-4-(QUINOLIN-6-IL-ACETIL)-[1,4]DIAZEPAN-1-IL]-3-(NAFTALEN-1-IL)PROPIONAMIDA. TAMBIEN SE REFIERE A UN PROCESO PARA LA PREPARACION; A UNA COMPOSICION QUE COMPRENDE ADEMAS UN FARMACO INMUNOSUPRESOR, INMUNOMODULADOR, ANTIINFLAMATORIO. EL COMPUESTO I ES UN INHIBIDOR DE LAS INTERACCIONES DEL ANTIGENO LFA-1 Y LA MOLECULA DE ADHESION INTRACELULAR ICAM-1, -ICAM-2, -ICAM-3, O INHIBEN LA INFLAMACION Y PUEDE SER UTIL PARA EL TRATAMIENTO DE LA ISQUEMIA, LESION POR REPERFUSION, INFARTO AL MIOCARDIO, EMBOLIA, ISQUEMIA DEL INTESTINO, DESORDENES INFLAMATORIOS AGUDOS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41681599A | 1999-10-13 | 1999-10-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20010745A1 true PE20010745A1 (es) | 2001-07-17 |
Family
ID=23651420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2000001087A PE20010745A1 (es) | 1999-10-13 | 2000-10-11 | Diazepanes como inhibidores de la interaccion del antigeno lfa-1 y la molecula de adhesion intracelular (icam) |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1220852B1 (es) |
| JP (1) | JP3889623B2 (es) |
| AT (1) | ATE316084T1 (es) |
| AU (1) | AU7918500A (es) |
| CO (1) | CO5251460A1 (es) |
| CY (1) | CY1105020T1 (es) |
| DE (1) | DE60025639T2 (es) |
| DK (1) | DK1220852T3 (es) |
| EC (1) | ECSP003707A (es) |
| ES (1) | ES2257328T3 (es) |
| PE (1) | PE20010745A1 (es) |
| WO (1) | WO2001027102A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6867203B2 (en) | 1998-12-29 | 2005-03-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds |
| US6110922A (en) | 1998-12-29 | 2000-08-29 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds |
| US6521619B2 (en) | 2000-06-29 | 2003-02-18 | Icos Corporation | Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents |
| WO2002002539A1 (en) | 2000-06-29 | 2002-01-10 | Abbott Laboratories | Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents |
| AR030817A1 (es) | 2000-10-02 | 2003-09-03 | Novartis Ag | Derivados de diazacicloalcanodiona |
| TWI311557B (en) | 2003-01-23 | 2009-07-01 | Novartis A | Pharmaceutically active diazepanes |
| GB0301561D0 (en) * | 2003-01-23 | 2003-02-26 | Novartis Ag | Organic compounds |
| PT1682537E (pt) | 2003-11-05 | 2012-06-20 | Sarcode Bioscience Inc | Moduladores de adesão celular |
| US7943660B2 (en) | 2005-04-15 | 2011-05-17 | Dominion Pharmakine S.L. | Inhibitors of the LFA-1/ICAM-1 interaction and uses thereof |
| GB0507918D0 (en) * | 2005-04-19 | 2005-05-25 | Novartis Ag | Organic compounds |
| CA2960117C (en) | 2005-05-17 | 2018-01-30 | Sarcode Bioscience Inc. | Lfa-1 antagonists for the treatment of eye disorders |
| US20090155176A1 (en) | 2007-10-19 | 2009-06-18 | Sarcode Corporation | Compositions and methods for treatment of diabetic retinopathy |
| US8080562B2 (en) | 2008-04-15 | 2011-12-20 | Sarcode Bioscience Inc. | Crystalline pharmaceutical and methods of preparation and use thereof |
| WO2011050175A1 (en) | 2009-10-21 | 2011-04-28 | Sarcode Corporation | Crystalline pharmaceutical and methods of preparation and use thereof |
| GB201016864D0 (en) | 2010-10-06 | 2010-11-17 | Univ Aston | Therapeutic methods |
| EP2877465A4 (en) | 2012-07-25 | 2016-05-11 | Sarcode Bioscience Inc | LFA-1 HEMMER AND POLYMORPH THEREOF |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL92011A0 (en) * | 1988-10-19 | 1990-07-12 | Abbott Lab | Heterocyclic peptide renin inhibitors |
| PL294870A1 (es) * | 1991-06-21 | 1993-02-08 | Hoechst Ag | |
| AU1083499A (en) * | 1997-10-21 | 1999-05-10 | Pharmacia & Upjohn Company | Thiadiazoles amides useful as antiinflammatory agents |
-
2000
- 2000-10-10 EC EC2000003707A patent/ECSP003707A/es unknown
- 2000-10-11 CO CO00077443A patent/CO5251460A1/es not_active Application Discontinuation
- 2000-10-11 PE PE2000001087A patent/PE20010745A1/es not_active Application Discontinuation
- 2000-10-11 ES ES00969490T patent/ES2257328T3/es not_active Expired - Lifetime
- 2000-10-11 WO PCT/EP2000/010025 patent/WO2001027102A1/en not_active Ceased
- 2000-10-11 JP JP2001530320A patent/JP3889623B2/ja not_active Expired - Fee Related
- 2000-10-11 DK DK00969490T patent/DK1220852T3/da active
- 2000-10-11 EP EP00969490A patent/EP1220852B1/en not_active Expired - Lifetime
- 2000-10-11 DE DE60025639T patent/DE60025639T2/de not_active Expired - Lifetime
- 2000-10-11 AU AU79185/00A patent/AU7918500A/en not_active Abandoned
- 2000-10-11 AT AT00969490T patent/ATE316084T1/de not_active IP Right Cessation
-
2006
- 2006-04-13 CY CY20061100521T patent/CY1105020T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1220852A1 (en) | 2002-07-10 |
| ATE316084T1 (de) | 2006-02-15 |
| EP1220852B1 (en) | 2006-01-18 |
| DK1220852T3 (da) | 2006-05-15 |
| ES2257328T3 (es) | 2006-08-01 |
| WO2001027102A1 (en) | 2001-04-19 |
| AU7918500A (en) | 2001-04-23 |
| JP2003511447A (ja) | 2003-03-25 |
| DE60025639D1 (de) | 2006-04-06 |
| CY1105020T1 (el) | 2010-03-03 |
| DE60025639T2 (de) | 2006-11-16 |
| ECSP003707A (es) | 2002-05-23 |
| JP3889623B2 (ja) | 2007-03-07 |
| CO5251460A1 (es) | 2003-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20010745A1 (es) | Diazepanes como inhibidores de la interaccion del antigeno lfa-1 y la molecula de adhesion intracelular (icam) | |
| PE20040079A1 (es) | Derivados de indolilmaleimida | |
| PE20021014A1 (es) | Derivados de glutaramida sustituida con n-fenpropilciclopentilo como inhibidores de nep para fsad | |
| PE20090423A1 (es) | Compuestos moduladores de sirtuina | |
| AR012264A1 (es) | Compuesto, composicion farmaceutica y metodo para obtener la composicion para prevenir o evitar una enfermedad asociada a actividad metaloproteasicaindeseada | |
| PE20060777A1 (es) | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas | |
| ES2191977T3 (es) | Soluciones y dispersiones en estado solido de farmacos poco solubles en agua. | |
| EA200000871A1 (ru) | Ингибиторы фосфолипазных ферментов | |
| EA200200619A1 (ru) | Непептидильные ингибиторы vla-4-зависимого связывания клеток, применяемые при лечении воспалительных, аутоимунных и респираторных заболеваний | |
| PE20011001A1 (es) | Compuestos heterociclicos como inhibidores del intercambio de sodio/protones | |
| PE20040775A1 (es) | DERIVADOS DE INDOL COMO AGONISTAS DE ADRENORECEPTORES ß2 | |
| PE20040155A1 (es) | Derivados aminoinazoles, procedimiento de preparacion e intermedios de este procedimiento a titulo de medicamentos y composiciones farmaceuticas que los contienen | |
| TR199900399T2 (xx) | Matris metaloproteaz inhibit�rleri olarak fosfinik asit amidleri. | |
| AR009358A1 (es) | Compuesto espirociclico inhibidor de la metaloproteasa | |
| TR199900400T2 (xx) | Heterosiklik metaloproteaz inhibit�rleri. | |
| JO2646B1 (en) | New differentiated cyclic compounds as beta - lactam inhibitors | |
| PE20050349A1 (es) | Compuestos de aril o heteroaril amida | |
| BRPI0409227B8 (pt) | "composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)" | |
| DE60036611D1 (de) | Indol-derivate als antientzündungs wirkstoffe | |
| EA200200253A1 (ru) | Ингибиторы клеточной адгезии | |
| EA199900332A1 (ru) | β-СУЛЬФОНИЛ ГИДРОКСАМОВЫЕ КИСЛОТЫ В КАЧЕСТВЕ ИНГИБИТОРОВ МАТРИЧНЫХ МЕТАЛЛОПРОТЕИНАЗ | |
| PE20091444A1 (es) | Derivados de isoxazolo-pirazina | |
| PE20030925A1 (es) | Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico | |
| PE20061426A1 (es) | Derivados de indol como inhibidores de la fosfolipasa a2 citosolica | |
| PE20100093A1 (es) | Derivados de acetileno |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |